Dr Reddys Laboratories Analyst Review May 2026

This Dr Reddys Laboratories analyst review for May 2026 covers the key data investors need for DRREDDY at its current price of Rs 1,280. Dr. Reddy’s Laboratories (NSE: DRREDDY) is one of India’s largest pharmaceutical companies with a market capitalisation of approximately Rs 2,13,000 crore, present in over 66 countries with strong APIs, generics, and biosimilars. The analyst consensus target of Rs 1,500 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether DRREDDY achieves that target through FY27.

Click Here – Get Free Investment Predictions

Dr Reddys Laboratories Company Snapshot May 2026

Dr. Reddy’s has been gaining US market share with ANDA filings for complex generics, gRevlimid (lenalidomide), and biosimilar launches. The Indian formulations business grows at 12 to 15 percent YoY in chronic therapy segments. The table below summarises the key data referenced in this Dr Reddys Laboratories analyst review.

Parameter	Value
NSE Ticker	DRREDDY
Sector	Pharmaceuticals
CMP (May 2026)	Rs 1,280
52 Week High	Rs 1,480
52 Week Low	Rs 1,110
Market Cap	Rs 2,13,000 Crore
Trailing P/E	22.00x
Analyst Consensus Target	Rs 1,500
Bull Case Target	Rs 1,750
Bear Case Target	Rs 1,050

Analyst Insight in This Dr Reddys Laboratories Analyst Review

Senior Research Analyst Ankit Jaiswal flags Dr Reddys Laboratories as a stock to watch in May 2026. At Rs 1,280, Ankit Jaiswal notes that the key levels for DRREDDY include support in the Rs 1,132 to Rs 1,216 band and resistance near Rs 1,357. He suggests watching Dr Reddys Laboratories for a potential move toward the consensus target of Rs 1,500, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Dr Reddys Laboratories analyst review and does not constitute a trade recommendation.

Technical Analysis in This Dr Reddys Laboratories Analyst Review

At Rs 1,280, DRREDDY is trading within its 52-week band of Rs 1,110 to Rs 1,480. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 1,132 to Rs 1,216 band while resistance is seen in the Rs 1,357 to Rs 1,390 zone. A sustained move above Rs 1,357 could open the path toward the analyst consensus of Rs 1,500.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 1,132 to Rs 1,216 – investors tracking this Dr Reddys Laboratories analyst review should watch for a stabilisation or bounce in this range as a potential accumulation signal.
• Resistance Zone: Rs 1,357 to Rs 1,390 – a sustained close above Rs 1,357 would be a positive breakout signal worth flagging.
• Medium-Term Target: The analyst consensus of Rs 1,500 represents the base-case upside for this Dr Reddys Laboratories analyst review.

Business Segment Analysis

US Generics and Complex Molecules (Key Revenue Driver)

This is the primary revenue and margin driver for Dr Reddys Laboratories, directly supporting the earnings trajectory toward the consensus target of Rs 1,500.

India Branded Formulations

This segment adds scale and diversification to Dr Reddys Laboratories’s business model and is a meaningful EPS contributor through FY27 and FY28.

Biosimilars (Rituximab, Trastuzumab) and APIs

This represents the medium-term growth frontier for Dr Reddys Laboratories and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Dr Reddys Laboratories Analyst Review

At Rs 1,280, Dr Reddys Laboratories trades at a trailing P/E of 22.00x. This Dr Reddys Laboratories analyst review presents three scenarios: a bull case of Rs 1,750 on strong earnings delivery, a base case of Rs 1,500 at consensus, and a bear case of Rs 1,050 if macro headwinds persist. Q1 FY27 results will be the first key validation point.

Scenario	Target Price	Key Condition
Bull Case	Rs 1,750	Strong earnings and sector tailwinds
Base Case (Consensus)	Rs 1,500	Moderate growth, analyst consensus estimate
Bear Case	Rs 1,050	Earnings miss or macro headwinds

Trade Outlook for Dr Reddys Laboratories

Based on the technical and fundamental analysis in this Dr Reddys Laboratories analyst review, investors might watch DRREDDY near the support zone of Rs 1,132 to Rs 1,216 for potential opportunities. A flag above Rs 1,357 could suggest improving momentum toward Rs 1,500. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Dr Reddys Laboratories in FY27

A well-rounded Dr Reddys Laboratories analyst review must assess downside risks. Key risks for Dr Reddys Laboratories include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in DRREDDY.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Dr Reddys Laboratories Analyst Review Verdict for 2026

This Dr Reddys Laboratories analyst review concludes that at Rs 1,280, DRREDDY offers a defined risk-reward with a consensus target of Rs 1,500. The 52-week range of Rs 1,110 to Rs 1,480 provides context on the current entry point. Use this Dr Reddys Laboratories analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on DRREDDY.

Frequently Asked Questions: Dr Reddys Laboratories Analyst Review 2026

What is the analyst target for Dr Reddys Laboratories in 2026?

The analyst consensus target is Rs 1,500, with a bull case of Rs 1,750 and a bear case of Rs 1,050. Monitor Q1 FY27 earnings for confirmation.

Is Dr Reddys Laboratories a good investment at Rs 1,280?

At Rs 1,280 with a P/E of 22.00x and a consensus target of Rs 1,500, this Dr Reddys Laboratories analyst review is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.

What is Dr Reddys Laboratories’s 52-week high and low?

The 52-week high is Rs 1,480 and the 52-week low is Rs 1,110. At Rs 1,280, DRREDDY is positioned within this range as noted in this Dr Reddys Laboratories analyst review.

What are the key risks for Dr Reddys Laboratories?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.

Where can I get live data and analyst targets for Dr Reddys Laboratories?

Track Dr Reddys Laboratories’s live price and analyst targets on the Univest Screener alongside professional financial advice.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.